title: Review of thymic hormones in cancer diagnosis and treatment.
abstract: The thymus is an endocrine organ. A unified, physiological concept of humoral regulations of the immune response has emerged in the last three decades. The thymus is the major site of production of immunocompetent T lymphocytes from their hematopoietic stem cells. This complex process required direct cell to cell, receptor based interactions, as well as in situ paracrine information via the numerous cytokines and thymic hormones produced by the cells of thymic microenvironment. Thymic hormones induce in situ T-cell marker differentiation, expression and functions. These polypeptide hormones have also been shown by means of immunocytochemistry to localize in the reticulo-epithelial (RE) cells of the thymic cellular microenvironment. Due to the great complexity of the intrathymic maturation sequence of T lymphocytes and the diverse immunophenotypically unique subpopulations of T lymphocytes, it is quite unlikely that a single thymic humoral factor could control all of the molecular steps and cell populations involved. It is much more likely that an extremely rich and diverse, but genetically determined, milieu is present within the thymus, and that thus the control of intrathymic T lymphocyte maturation and the functional maturation of T cells involves the orchestral interaction of various thymic-specific factors and other molecules during the differentiation process. Thymosin fraction 5 and its constituent peptides influence several properties of lymphocytes including cyclic nucleotide levels, migration inhibitory factor production, T-dependent antibody production, as well as the expression of various cell surface maturation/differentiation markers. Recently, derivatives of thymic hormones, mostly of thymosins, have been detected as products of neoplastically transformed cells and employed in the early diagnosis of neoplasms. In clinical trials, thymic hormones strengthen the effects of immunomodulators in immunodeficiencies, autoimmune diseases, and neoplastic malignancies. Combined chemo-immunotherapeutical anti-cancer treatment seems to be more efficacious than chemotherapy alone, and the significant hematopoietic toxicity associated with most chemotherapeutical clinical trials can be reduced significantly by the addition of immunotherapy.
authors.affiliation: Department of Pathology, University of Southern California, Los Angeles, USA. Bodey18@aol.com
authors.forename: B
authors.initials: B
authors.lastname: Bodey
authors.forename: B
authors.initials: B
authors.lastname: Bodey
authors.forename: S E
authors.initials: SE
authors.lastname: Siegel
authors.forename: H E
authors.initials: HE
authors.lastname: Kaiser
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000628:therapy*; D009842:Oligopeptides / Q000627:therapeutic use; D011498:Protein Precursors / Q000032:analysis; D000077596:Thymalfasin; D016305:Thymopentin / Q000627:therapeutic use; D013947:Thymosin / Q000031:analogs & derivatives / Q000032:analysis / Q000627:therapeutic use; D013951:Thymus Hormones / Q000032:analysis / Q000627:therapeutic use*
chemical_list: D014408:Biomarkers, Tumor; D009842:Oligopeptides; D011498:Protein Precursors; D013951:Thymus Hormones; C040782:prothymosin alpha; C033782:thymosin fraction 5; C064563:thymic humoral factor gamma 2; D013947:Thymosin; C039302:thymosin beta(10); D016305:Thymopentin; D000077596:Thymalfasin